Low <i>In Vitro</i> Antifungal Activity of Tavaborole against Yeasts and Molds from Onychomycosis

Abstract

The <i>in vitro</i> activity of tavaborole, an FDA-approved antifungal drug, was compared to that of four antifungal agents against 170 clinical fungal isolates originating from patients with onychomycosis. Tavaborole had low activity against all isolates compared to itraconazole, terbinafine, and fluconazole, the principal choices for treatment of onychomycosis. Thus, it appears that tavaborole is not a candidate for the treatment of onychomycosis due to <i>Candida</i> species, <i>Aspergillus</i> species, and dermatophytes.